New treatment significantly reduces cardiovascular events when combined with statins

November 12, 2018 by Graciela Gutierrez, Baylor College of Medicine
Credit: CC0 Public Domain

Statins are the most commonly used treatment for cardiovascular disease. Despite reducing certain risk factors, if triglyceride levels remain high with use of statins, there is still a significant risk for heart attack, stroke or other ischemic events.

In a study in the current edition of the New England Journal of Medicine, researchers at Baylor College of Medicine who are a part of the Reduction of Cardiovascular Events with Icosapent Ethyl-Intervention Trial (REDUCE-IT) have shown that a particular treatment significantly reduced cardiovascular events, including , in patients who continue to have high on statin therapy. These findings could lead to a more effective and life-saving treatment option when used with other combinations of drugs to treat cardiovascular disease.

REDUCE-IT researchers are studying icosapent ethyl, a highly purified eicosapentaenoic acid (EPA) ethyl ester, which is an purified from fish oil. The main goal of the study is to determine whether treatment with this drug reduces ischemic events in statin-treated patients with hypertriglyceridemia.

"For the last three decades, we have focused on drugs that lower cholesterol to reduce cardiovascular events. Recent genetic studies have shown that triglycerides play an important role in heart disease, but we have not had outcome studies to test if adding another therapy to a statin would help individuals with high triglycerides and heart disease or diabetes," said Dr. Christie Ballantyne, professor of medicine and chief of the sections of cardiology and cardiovascular research at Baylor.

The multicenter, double-blind study followed more than 8,000 participants, some for up to six years. Some were given a 4 gram daily dosage of icosapent ethyl ester while others were given a placebo. All participants were being treated with statins and had a triglyceride level of greater than or equal to 135 mg/dL and less than 500 mg/dL with established or diabetes and other risk factors. Triglyceride levels are considered healthy when they are less than 100 mg/dL.

The study was focused on clinical endpoints. The primary endpoint showed a 25 percent reduction in cardiovascular death, nonfatal myocardial infarction, nonfatal stroke, coronary revascularization or unstable angina, and the secondary endpoint showed a 26 percent reduction in cardiovascular death, nonfatal myocardial infarction or nonfatal stroke.

"Our group has been studying omega 3 fatty acids for over 20 years and have been working on EPA for almost a decade. These results support the previous finding of a Japanese study, Japan EPA Lipid Intervention Study, which showed that EPA reduced cardiovascular events by 19 percent in individuals with high cholesterol on a low-dose of . However, low doses of a mixture of EPA and docosahexaenoic acid, another omega-3 fatty acid, have not shown benefit in reducing ."

The next step will be to understand what mechanisms are at play that help in the reduction of ischemic events when treated with EPA as this agent is known to have many biological activities in addition to the effects on lipids.

Explore further: Jury still out on aspirin a day to prevent heart attack and stroke

More information: Deepak L. Bhatt et al. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia, New England Journal of Medicine (2018). DOI: 10.1056/NEJMoa1812792

Related Stories

Jury still out on aspirin a day to prevent heart attack and stroke

August 26, 2018
The jury is still out on whether people at moderate risk of a first heart attack or stroke should take daily aspirin to lower their risk, according to late breaking results from the ARRIVE study presented today in a Hot Line ...

Fenofibrate may reduce heart disease risk in some patients with type 2 diabetes

December 28, 2016
A new study shows that the drug fenofibrate might reduce the risk of cardiovascular events in patients with type 2 diabetes who have high levels of triglycerides and low levels of "good" cholesterol, despite being treated ...

Ezetimibe reduces cardiovascular events in diabetics with recent acute coronary syndrome

August 30, 2015
Ezetimibe reduces cardiovascular events in patients with diabetes and a recent acute coronary syndrome, according to a subgroup analysis of the IMPROVE-IT trial presented at ESC Congress today by co-principal investigator ...

Anacetrapib reduces risk of serious cardiovascular events in high risk patients on statins

August 29, 2017
Anacetrapib, an inhibitor of cholesteryl ester transfer protein (CETP) activity, lowers the risk of heart attack and related cardiovascular complications in patients receiving intensive statin treatment, according to late-breaking ...

Patients with high lipoprotein(a) levels may benefit from taking PCSK9 inhibitors

May 21, 2018
Lipoprotein(a) is a variant of LDL (low-density lipoprotein) cholesterol, and large amounts of data have shown that higher lipoprotein(a) levels are associated with an increased risk of cardiovascular events. Atherosclerosis ...

Lipid tx cuts cardiovascular risk with type 1 diabetes

April 22, 2016
(HealthDay)—The risk of cardiovascular disease (CVD) and cardiovascular death is 22 to 44 percent lower among individuals with type 1 diabetes treated with lipid-lowering therapy (LLT), according to a study published online ...

Recommended for you

Research team traces pathway to cardioprotection in post-ischemic heart failure

December 11, 2018
During an ischemic attack, the heart is temporarily robbed of its blood supply. The aftermath is devastating: reduced heart contractility, heart cell death, and heart failure. Contributing to these detrimental changes is ...

Study reveals new link between atrial fibrillation and mutations in heart disease gene

December 11, 2018
Atrial fibrillation (Afib), a heart condition that causes a rapid, irregular heartbeat that increases a person's risk of stroke and heart failure, is fairly common among older adults. However, its early onset form is relatively ...

Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes

December 11, 2018
Researchers have found that incidence of heart failure was around two-fold higher in people with diabetes.

Study: Age, race differences determine risk of stroke in women and men

December 11, 2018
A new study found that, between the ages of 45 and 74 years, white women were less likely to have a stroke than white men, but at age 75 and older, there was no difference in stroke risk between white women and men. In contrast, ...

Macrophage cells key to helping heart repair—and potentially regenerate, new study finds

December 11, 2018
Scientists at the Peter Munk Cardiac Centre have identified the type of cell key to helping the heart repair and potentially regenerate following a heart attack.

Possible connection between cardiovascular disease and living near oil and gas wells

December 11, 2018
Researchers at the Colorado School of Public Health have found a possible connection between the intensity of oil and gas exploration in an area and early indicators of cardiovascular disease among nearby residents.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.